Acrivon Therapeutics Inc.... (ACRV)
Acrivon Therapeutics Common Stock Statistics
Share Statistics
Acrivon Therapeutics Common Stock has 31.35M shares outstanding. The number of shares has increased by 1.54% in one year.
| Shares Outstanding | 31.35M |
| Shares Change (YoY) | 1.54% |
| Shares Change (QoQ) | 0.69% |
| Owned by Institutions (%) | 60.39% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,927 |
| FTD / Avg. Volume | 1.83% |
Short Selling Information
The latest short interest is 710.5K, so 2.28% of the outstanding shares have been sold short.
| Short Interest | 710.5K |
| Short % of Shares Out | 2.28% |
| Short % of Float | 5.94% |
| Short Ratio (days to cover) | 1.91 |
Valuation Ratios
The PE ratio is -25.25 and the forward PE ratio is -0.58. Acrivon Therapeutics Common Stock's PEG ratio is 0.28.
| PE Ratio | -25.25 |
| Forward PE | -0.58 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 11.51 |
| P/FCF Ratio | -29.72 |
| PEG Ratio | 0.28 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acrivon Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.55 |
| Quick Ratio | 10.55 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,074,080 |
| Employee Count | 75 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.92% in the last 52 weeks. The beta is 1.78, so Acrivon Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 1.78 |
| 52-Week Price Change | -83.92% |
| 50-Day Moving Average | 3.52 |
| 200-Day Moving Average | 6.3 |
| Relative Strength Index (RSI) | 30.21 |
| Average Volume (20 Days) | 486,632 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.2M |
| Net Income | -80.56M |
| EBITDA | -89.2M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 39.82M in cash and 3.65M in debt, giving a net cash position of 36.17M.
| Cash & Cash Equivalents | 39.82M |
| Total Debt | 3.65M |
| Net Cash | 36.17M |
| Retained Earnings | -196.98M |
| Total Assets | 196.59M |
| Working Capital | 164.41M |
Cash Flow
In the last 12 months, operating cash flow was -65.67M and capital expenditures -2.77M, giving a free cash flow of -68.44M.
| Operating Cash Flow | -65.67M |
| Capital Expenditures | -2.77M |
| Free Cash Flow | -68.44M |
| FCF Per Share | -0.2 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ACRV is $17, which is 1150% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 1150% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 2 |